EBITDA for Edwards Lifesciences (EW)
According to Edwards Lifesciences's latest reported financial statements, the company's current EBITDA (TTM) is $1.44B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$1.44B
YoY change
-17.0%
5Y CAGR
+5.9%
Peak year (2022)
$1.96B
Cumulative EBITDA
$19.47B
EBITDA history chart for Edwards Lifesciences (EW) from 1999 to 2025
EBITDA history table for Edwards Lifesciences (EW) from 1999 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $1.43B | -17.0% | ||
| 2024 | $1.72B | +12.3% | ||
| 2023 | $1.53B | -21.7% | ||
| 2022 | $1.96B | +3.7% | ||
| 2021 | $1.89B | +75.9% | ||
| 2020 | $1.07B | -17.9% | ||
| 2019 | $1.31B | +50.0% | ||
| 2018 | $872.20M | -23.5% | ||
| 2017 | $1.14B | +37.8% | ||
| 2016 | $827.10M | +17.1% | ||
| 2015 | $706.60M | -42.7% | ||
| 2014 | $1.23B | +109.3% | ||
| 2013 | $589.80M | +30.3% | ||
| 2012 | $452.80M | +31.4% | ||
| 2011 | $344.70M | +5.4% | ||
| 2010 | $327.10M | -10.6% | ||
| 2009 | $365.80M | +61.0% | ||
| 2008 | $227.20M | +6.3% | ||
| 2007 | $213.70M | -10.8% | ||
| 2006 | $239.60M | +29.4% | ||
| 2005 | $185.20M | +85.2% | ||
| 2004 | $100.00M | -45.7% | ||
| 2003 | $184.00M | +98.9% | ||
| 2002 | $92.50M | +14.1% | ||
| 2001 | $81.10M | -52.0% | ||
| 2000 | $169.00M | -15.9% | ||
| 1999 | $201.00M | — |
EBITDA values are taken from Edwards Lifesciences's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, Edwards Lifesciences (EW) EBITDA totalled $1.43B – declined 17.0% year-over-year.
Edwards Lifesciences EBITDA has recorded the values shown across consecutive periods, with a +5.9% compound annual growth rate over 2020–2025 (5 years).
Edwards Lifesciences EBITDA peaked at $1.96B in 2022; the latest annual figure is $1.43B in 2025 (27.1% below peak).
Across the available history, EBITDA reached its high of $1.96B in 2022 and its low of $81.10M in 2001.
Among 8 Healthcare peers, Edwards Lifesciences (EW) ranks 9th; the peer median for EBITDA is $24.21B.
Edwards Lifesciences EBITDA by Year
Edwards Lifesciences EBITDA 2025: $1.43B
Edwards Lifesciences EBITDA in 2025 was $1.43B, declined 17.0% below 2024.
Edwards Lifesciences EBITDA 2024: $1.72B
Edwards Lifesciences EBITDA in 2024 was $1.72B, grew 12.3% from 2023.
Edwards Lifesciences EBITDA 2023: $1.53B
Edwards Lifesciences EBITDA in 2023 was $1.53B, declined 21.7% below 2022.
Edwards Lifesciences EBITDA 2022: $1.96B
Edwards Lifesciences EBITDA in 2022 was $1.96B, edged up 3.7% from 2021. This figure represents the highest annual value in the available history.
Edwards Lifesciences EBITDA 2021: $1.89B
Edwards Lifesciences EBITDA in 2021 was $1.89B.
See more financial history for Edwards Lifesciences (EW).
Sector peers — EBITDA
Companies in the same sector as Edwards Lifesciences, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is Edwards Lifesciences's EBITDA?
- Latest reported EBITDA for Edwards Lifesciences (EW) is $1.44B (period ending March 31, 2026).
How has Edwards Lifesciences EBITDA changed year-over-year?
- Edwards Lifesciences (EW) EBITDA changed -17.0% year-over-year on the latest annual filing.
What is the long-term growth rate of Edwards Lifesciences EBITDA?
- Edwards Lifesciences (EW) EBITDA compound annual growth rate is +5.9% over the most recent 5 years available.
When did Edwards Lifesciences EBITDA hit its highest annual value?
- Edwards Lifesciences EBITDA reached its highest annual value of $1.96B in 2022.
What was Edwards Lifesciences EBITDA in 2024?
- Edwards Lifesciences (EW) EBITDA in 2024 was $1.72B.
What was Edwards Lifesciences EBITDA in 2025?
- Edwards Lifesciences (EW) EBITDA in 2025 was $1.43B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
EW Overview
Company profile, financial tools, and key metrics
EW Revenue Counter
Earns $199.88 every second. See per minute, hour, and day.
EW Earnings Counter
Earns $34.65 per second net profit. See per minute, hour, and day.
EW Economic Scale
Exceeds Fiji's GDP. Compare with world economies.
EW What If Invested
What if you had invested $1,000? See historical returns from any date.
EW How It Makes Money
Discover visual breakdown of $6.30B in revenue — where it comes from and where it goes.
EW Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
EW Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
EW Daily Price Character
Balanced · 50.0% historical win rate (green days). Streaks & record days.
EW Buybacks
0.93% TTM buyback yield. Shareholder yield & SBC comparison.
EW Stock Split History
3 splits on record. Dates, ratios, and cumulative multiple.